The Galveston County Daily NewsWILMINGTON, Del.--(BUSINESS WIRE)--Oct 18, 2025--
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTIN
57
People Human Interest
AlterNet
New York Post
Crooks and Liars
Cowboy State Daily
Arizona's Family
Associated Press Top News
CBS News
The Columbian
The Daily Beast